<DOC>
	<DOCNO>NCT02772718</DOCNO>
	<brief_summary>The purpose study evaluate safety clinical pharmacology XOMA 358 patient hypoglycemia gastric bypass surgery .</brief_summary>
	<brief_title>An Open-Label Study XOMA 358 Patients With Hypoglycemia After Gastric Bypass Surgery</brief_title>
	<detailed_description />
	<mesh_term>Hypoglycemia</mesh_term>
	<criteria>Aged least 18 year age Body Mass Index &lt; 35 kg/m2 baseline , unless discuss Medical Monitor patient higher body mass index significant medical comorbidities would confound ability ass safety efficacy study drug . Received gastric bypass surgery 1 year dose Occurrence postprandial hypoglycemia ( blood glucose less 60mg/dL ) Baseline provocation assessment and/or continuous glucose monitoring , define protocol . History type 1 diabetes Planned use follow medication Day 3 ( Part 1 ) : Any agent hypoglycemia , diazoxide octreotide Antihyperglycemic agent , include subcutaneous insulin therapy , sulfonylurea , SGLT2 inhibitor , GLP1 agonists Systemic glucocorticoid Î² agonist may affect glucose metabolism Longacting somatostatin analog glucoseaffecting medication During Part 2 , follow therapy prohibit specify : Tramadol medication use treatment postbariatric surgery hypoglycemia may cause hypoglycemia fluctuation blood glucose level . Acetaminophencontaining product period continuous glucose monitoring . Medications tramadol may cause hypoglycemia fluctuation blood glucose level , , use medication subject restriction describe study . Acetaminophen interfere accuracy glucose sensor continuous glucose monitoring system , therefore , prohibit continuous glucose monitoring . Major general surgery within 3 month study entry anticipate study period Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hypoglycemia</keyword>
</DOC>